Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision.
Faricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal perfusion. While anti-vascular endothelial growth factor (VEGF) agents suppress neovascularization, prolonged VEGF blockade may impair choriocapillaris health. Ang-2 inhibition, by promoting Tie2 activation and vascular stability, may protect choriocapillaris and reduce widespread retinal edema and hemorrhages observed in type 3 MNV.
Finally, while treat-and-extend is widely used in practice, existing trials (TENAYA, LUCERNE) applied broader extension intervals than typically used clinically. In type 3 MNV, where undertreatment carries severe consequences, a more stringent faricimab-based treat-and-extend regimen with 2-week interval adjustments warrants investigation.

Start Date23 Sep 2025

Sponsor / Collaborator

Kim'S Eye Hospital

CTIS2023-509829-52-00

/ RecruitingPhase 4IIT

A phase IV study of Faricimab to explore associations of visual acuity benefits and changes in vascular integrity using adaptive optics in patients with diabetic macular edema

Start Date01 Sep 2025

Sponsor / Collaborator

Martin-Luther-Universität Halle-Wittenberg

ChiCTR2500106303

/ Not yet recruitingPhase 4IIT

A prospective study to evaluate the alterations of early macular microcirculation following intravitreal injection of faricimab for macular edema secondary to branch retinal vein occlusion

Start Date01 Sep 2025

Sponsor / Collaborator

The Second Affiliated Hospital of Chongqing Medical University

[+1]

100 Clinical Results associated with Faricimab

100 Translational Medicine associated with Faricimab

100 Patents (Medical) associated with Faricimab

390

Literatures (Medical) associated with Faricimab

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan

Article

Author: Igarashi, Ataru ; Sakashita, Naotaka ; Shoji, Ayako ; Higashi, Kentaro ; Tsujimura, Jun ; Ohno, Shinya ; Yanagi, Yasuo

OBJECTIVE:

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.

METHODS:

A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.

RESULTS:

In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.

CONCLUSIONS:

When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland

Article

Author: Quist, S.W. ; Maamari, S. ; Boer, M. ; Ambresin, Aude ; Barthelmes, D.

OBJECTIVE:

This study compares the direct healthcare costs of anti-VEGF therapies, including treat-and-extend (T&E) and other durable regimens, for unilateral neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in Switzerland.

METHODS:

An adapted cost-minimisation model estimated healthcare costs over two years for aflibercept 2 mg, aflibercept 8 mg, faricimab, ranibizumab, and ranibizumab biosimilars using clinical trial injection frequencies. Break-even analyses identified the medication prices and injection frequencies required for higher-cost therapies to achieve cost parity with the least expensive options. A one-way sensitivity analysis (OWSA) assessed key drivers of cost outcomes.

RESULTS:

Aflibercept 8 mg was estimated to be associated with the lowest treatment costs for both indications (CHF 11,814 for nAMD; CHF 11,242 for DMO). Faricimab (CHF 13,737) and aflibercept 2 mg (CHF 15,243) followed in nAMD and DMO. Ranibizumab and its biosimilars incurred the highest costs: for nAMD, biosimilars ranged from CHF 16,243 to CHF 17,497 and the reference product reached CHF 18,424; for DMO, biosimilars ranged from CHF 18,187 to CHF 19,596, with the reference product at CHF 20,637. Break-even analyses for nAMD showed that prices would need to drop by -22% (faricimab, CHF 644) to -64% (ranibizumab reference, CHF 218) relative to aflibercept 8 mg. For DMO, reductions ranged from -42% (aflibercept 2 mg, CHF 493) to -81% (ranibizumab reference, CHF 114). The OWSA highlighted medication price and injection frequency as primary cost drivers.

CONCLUSIONS:

This study estimated that the potentially minimized injection frequency of aflibercept 8 mg in a clinical trial regimen may result in the lowest treatment costs for nAMD and DMO, followed by faricimab and aflibercept 2 mg, respectively.

01 Dec 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis

Review

Author: Zhang, Charles ; Yannuzzi, Nicolas A ; Albini, Thomas A ; Leung, Nicholas ; Zhu, Daniel ; Lai, Daniel A ; Aboukasm, Georges

TOPIC:

Faricimab in the treatment of treatment-resistant neovascular age-related macular degeneration (nAMD).

CLINICAL RELEVANCE:

While many studies on faricimab in treatment-resistant eyes have reported improvements in retinal thickness (RT), the impact on visual acuity (VA) remains inconsistent. Additionally, variability in dosing protocols-with some studies utilizing loading interval for the first 3 injections while others continuing at the prior injection interval-introduces further uncertainty regarding the optimal treatment strategy. Understanding these differences is essential for guiding clinical decision-making and maximizing patient outcomes.

METHODS:

This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (CRD420251000088). A systematic search of PubMed, Embase, and Scopus (February 3, 2025) identified studies evaluating the effects of switching to faricimab in treatment-resistant nAMD. Inclusion criteria required patients to have received ≥3 prior anti-VEGF injections and ≥3 faricimab injections, with reported outcomes on RT, VA, fluid status, or injection intervals. Outcomes were measured following completion of loading dose and at last follow up, ranging from 3 months to 1.5 years. Studies were assessed for bias using ROBINS-I and NIH Quality Assessment tool and assessed for certainty of evidence using GRADE. Meta-analyses were conducted using mean differences, odds ratio, and random-effects models.

RESULTS:

Fourteen studies (926 eyes) met inclusion criteria. Switching to faricimab significantly reduced RT by 46.67 µm (95% CI: 35.91-57.42, I² = 0%, 721 eyes). Eyes that followed a loading interval were found to have greater reduction in RT than those that did not (I² = 74.1%, 640 eyes). The odds of achieving a dry macula increased 4.35-fold (95% CI: 2.95-6.42, I² = 64%, 379 eyes). Eyes with baseline VA <65 ETDRS letters showed a gain of 3.16 letters (95% CI: 0.80-5.52, I² = 0%, 439 eyes). Injection intervals were extended by 1.56 weeks (95% CI: 0.71-2.40, I² = 86%, 591 eyes). Using GRADE, 4 outcomes were graded as either very low (VA, dryness, and treatment interval) or low (RT).

CONCLUSION:

Switching to faricimab in treatment-resistant nAMD eyes significantly improved RT with no change in VA. This effect was greater with a loading interval protocol. Overall, there was an extension of injection intervals. Further prospective studies are needed to optimize dosing strategies and assess long-term efficacy.

291

News (Medical) associated with Faricimab

20 Nov 2025

·www.fiercepharma.com

With 2 FDA nods for Eylea HD, Regeneron is 'no longer fighting Vabysmo with both hands tied behind its back,' analyst says

Two long-awaited FDA approvals for Regeneron and Bayer's Eylea HD will allow the companies to compete on more equal footing with Roche's Vabysmo. After months of back-and-and forth with the FDA and a third-party manufacturer, Regeneron has secured two long-awaited approvals for Eylea HD, gaining a new indication and a more flexible dosing option for the eye disease drug.The FDA has signed off on Eylea HD for patients with macular edema following retinal vein occlusion (RVO), making it the first treatment available in the indication with dosing up to every eight weeks. The agency also endorsed a monthly dosing option for Eylea HD across each of its approved indications, which include wet age-related macular degeneration (wAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and now RVO.The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's long-acting treatment can be administered up to every four months, as opposed to Regeneron’s original 2 mg version of Eylea, which has a maximum dosing interval of every two months. Regeneron and partner Bayer's Eylea HD can also be dosed up to every four months in wAMD and DME, but the companies have still been playing catch-up with Roche's formidable eye disease med.Now, Eylea HD is “no longer fighting Vabysmo with both hands tied behind its back,” Evercore ISI analyst Cory Kasimov wrote in a Thursday investor note, adding that the new approvals “should enable a true inflection in market adoption.”A key potential approval still awaits for Eylea HD's prefilled syringe (PFS), Kasimov added. Again, Regeneron and Bayer are playing catch-up as Roche earned its PFS go-ahead from the FDA in July of 2024.Last month, the FDA rejected Regeneron’s bid for a PFS approval, citing unresolved issues at the Indiana plant of its manufacturing partner, Novo Nordisk. Regeneron said that it continues to work with Novo to resolve problems at the former Catalent plant that were identified in a July inspection. The company plans to resubmit an application, which will include an alternate PFS manufacturer, in January.As for the monthly dosing option for Eylea HD, Regeneron said that the new nod is key because some patients in trials did not maintain a response with extended dosing intervals after successful responses to initial monthly doses. After an initial monthly dosing regimen, Eylea HD was previously approved for dosing every 8 to 16 weeks for patients with wAMD and DME and every 8 to 12 weeks for those with DR. “Prior to this approval, docs would be on the hook for the drug cost if Eylea HD required more frequent dosing than on the label,” Kasimov wrote. “The inclusion of (four-week) dosing will now allow for payers to reimburse here. Based off our KOL feedback, the lack of (four-week) dosing on the label had been a source of headache for retina docs. This update is a win on this front.”Meanwhile, Eylea HD’s RVO label does not have Vabysmo’s six-month dosing limitation, Kasimov pointed out, allowing the Regeneron medicine to “now have a rare advantage” over Roche’s drug.“Eylea HD is the first treatment for retinal vein occlusion that can potentially cut the number of injections that patients receive in half compared to existing therapies," George Yancopoulos, M.D., Ph.D., Regeneron’s co-founder and chief scientific officer, said in a release. "And with the addition of a monthly dosing option for all four approved Eylea HD indications, physicians now have greater flexibility and optionality to tailor treatment to meet individual patient needs.”In August, the FDA extended its target action dates for the RVO and flexible dosing applications because of the manufacturing issues at the Indiana plant.Three weeks ago, Regeneron reported that sales of Eylea HD reached an all-time high of $392 in the third quarter. The bad news, however, was that while sales from Eylea HD increased by 29% sequentially, it didn’t translate to a similar bump in overall U.S. revenue for the Eylea family of eye medications. From Q2 to Q3, franchise sales increased only marginally—from $1.535 billion to $1.537 billion. Meanwhile, Roche reported that worldwide third-quarter sales of Vabysmo were up 8% sequentially, from 947 million CHF ($1.09 billion) in the second quarter to 1,022 million CHF ($1.18 billion) in the third quarter.The companies are also battling new competition from biosimilars as Eylea has lost its patent protection. In the third quarter, Amgen posted sales of its Eylea biosimilar Pavblu at $213 million.

Drug Approval

20 Nov 2025

·firstwordpharma.com

Regeneron's HD Eylea wins RVO OK from FDA, pre-filled syringe resubmission due next year

After months of regulatory setbacks for the high-dose (HD) version of Eylea (aflibercept), Regeneron Pharmaceuticals notched two wins on Wednesday — but a decision on the VEGF inhibitor's pre-filled syringe formulation won't come until next year. The news sent Regeneron's shares up about 5% on Thursday. The FDA approved the 8-mg Eylea HD injection for patients with macular oedema following retinal vein occlusion (RVO), and can be dosed up to every 8 weeks following an initial monthly dosing period. The US regulator also gave Eylea HD a nod for every 4-week dosing in all its approved indications, including wet age-related macular degeneration (AMD), diabetic macular oedema (DME), diabetic retinopathy (DR) and RVO."We believe these approvals further position Eylea HD as a treatment of choice for certain retinal diseases," said George Yancopoulos, Regeneron's chief scientist. "And with the addition of a monthly dosing option for all four approved Eylea HD indications, physicians now have greater flexibility and optionality to tailor treatment to meet individual patient needs."The positive rulings in RVO and monthly dosing come after the FDA extended both applications' deadlines into the fourth quarter; the agency had been expected to make a decision in August. Still, a delay — rather than an outright rejection — was welcomed by investors at the time (see – Vital Signs: Can Regeneron break its CRL streak?).That's because Eylea has received two separate complete response letters (CRLs) this year. In April, the FDA denied Regeneron's request to add every-24-week dosing to Eylea HD's label in AMD, DME and DR. The drugmaker's attempts to win approval for a pre-filled syringe version have also been rebuffed due to unresolved manufacturing issues at a Catalent facility. After pushing back its decision, the US regulator ultimately handed down a CRL last month. Regeneron said Wednesday it plans to submit a fresh pre-filled syringe application using a different manufacturer in January. With standard Eylea sales plummeting, the HD formulation was meant to stem the franchise's bleeding, but Regeneron has struggled to convert patients to the updated version in the face of competition from biosimilars and Roche's Vabysmo (faricimab-svoa) (see – Vital Signs: Eylea angst tanks Regeneron, sets up Amgen faceoff and Physician Views Results: Appetite for biosim Eylea healthy, but high-dose adoption could limit brand erosion).Regeron has pegged the pre-filled syringe formulation, as well as every-four-week dosing, as added convenience factors that are expected to win prescribers back into its corner.

Drug Approval

20 Nov 2025

·www.pharmaceutical-technology.com

Regeneron’s Eylea franchise boosted by pair of FDA approvals

This marks the fourth approval for the high-dose version of Eylea, with it already indicated for three other ophthalmic conditions. Credit: Piotr Swat via Shutterstock.com. Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication to its label and offering a more convenient dosing option, as the drugmaker looks to stave off Roche’s rival product and biosimilar pressures. The FDA has authorised the vascular endothelial growth factor (VEGF) inhibitor for the treatment of patients with macular oedema following retinal vein occlusion (RVO), with a dosing schedule of up to every eight-weeks following an initial monthly dosing period. This marks the fourth approval for the high-dose version of Eylea, with it already indicated for the treatment of wet age-related macular degeneration (wAMD), diabetic macular oedema (DME), and diabetic retinopathy (DR). The latest approval was based on data from the Phase III QUASAR trial (NCT05850520). This demonstrated Eylea HD’s non-inferiority to Eylea in achieving visual acuity gains in patients with RVO, a condition where a blood clot blocks a retinal vein. The condition leads to blurred or lost vision. In a further boost to Eylea HD’s outlook, the FDA also approved a monthly dosing option for some patients across the approved indications. While the injection has dosing intervals either every eight, 12, or 16 weeks, depending on the indication, patients who do not maintain a response at extended intervals could benefit from resuming every four-week dosing. Regeneron’s chief scientific officer George Yancopoulos said: ” Eylea HD is the first treatment for retinal vein occlusion that can potentially cut the number of injections that patients receive in half compared to existing therapies. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence “And with the addition of a monthly dosing option for all four approved Eylea HD indications, physicians now have greater flexibility and optionality to tailor treatment to meet individual patient needs.” A “positive catalyst” for Eylea HD’s growth Eylea HD, the high-dose version of Eylea, is a major growth driver for Regeneron. Sales for both versions of Eylea totalled $1.1bn in the US in Q3 2025, up 28% from Q3 2024. Regeneron has US rights to the drug while Bayer commercialises it elsewhere. Regeneron has been trying to shift its patient base to Eylea HD, which allows longer intervals between injections. The Eylea franchise is Regeneron’s best-selling product after Dupixent (dupilumab). Eylea HD sales are forecast to reach $2.74bn by 2031, according to GlobalData’s Pharma Intelligence Center. GlobalData is the parent company of Pharmaceutical Technology . The move to increase Eylea HD uptake comes as Regeneron’s position in the eye disease market has been significantly eroded by Roche’s rival drug Vabysmo (faricimab). Multiple Eylea biosimilars have also flooded the US market amid patent exclusivity loss, which has exerted further pressure on the brand. In a research note, Citi analysts said the latest approvals are a “positive catalyst for the Eylea franchise, enabling it to more effectively contend with Roche’s Vabysmo in the competitive anti-VEGF market”. The FDA approvals mark the end of a difficult year for the franchise in the regulatory arena. Decisions by the agency were delayed by issues found at a Novo Nordisk-owned manufacturing site that Regeneron uses for filling vials of Eylea. Novo acquired the Indiana plant as part of its $16.5bn acquisition of CDMO Catalent in December 2024. The plant’s shortcomings are still dashing approval hopes for a pre-filled syringe version of Eylea HD. The FDA rejected this formulation of the drug in October 2025. Pre-filled syringes would further bolster the franchise with more efficient administration. Regeneron said it “continues to coordinate with Catalent Indiana (part of Novo Nordisk) as it works to resolve the outstanding issues identified from a July 2025 FDA general site inspection”. Citi analysts added: “While pre-filled syringe approval is still pending, the immediate impact of the RVO and monthly dosing approvals could drive an inflection in Eylea-HD’s performance as early as Q1 2026, helping counteract prevailing headwinds.” Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

AcquisitionDrug ApprovalPhase 3Clinical Result

100 Deals associated with Faricimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11516	Faricimab	-	DB15303

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angioid Streaks	Japan	Chugai Pharmaceutical Co., Ltd.	19 May 2025
Retinal vein occlusion-related macular edema	Australia	Roche Products Pty Ltd.	08 Aug 2022
Age Related Macular Degeneration	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Choroidal Neovascularization	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Dystrophy, Macular	Japan	Chugai Pharmaceutical Co., Ltd.	28 Mar 2022
Diabetic macular oedema	United States	Genentech, Inc.	28 Jan 2022
Wet age-related macular degeneration	United States	Genentech, Inc.	28 Jan 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinal Vein Occlusion	NDA/BLA	United States	Roche Holding AG	09 May 2023
Proliferative retinopathy with diabetes mellitus	Phase 3	United States	Genentech, Inc.	04 Aug 2025
Myopic choroidal neovascularization	Phase 3	China	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	China	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Australia	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	Roche China Holding Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	France	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	F. Hoffmann-La Roche Ltd.	28 Feb 2024
Myopic choroidal neovascularization	Phase 3	Germany	Roche China Holding Ltd.	28 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03622593 \| NCT03622580 (YOSEMITE, Pubmed \| Retina)	Phase 3	Diabetic macular oedema	1,700	Faricimab Q8W	kydxrpgkrf(nizezizqkf) = tnegeawxpp hagxwhbnlq (zrvaqjwjdi ) View more	Positive	01 Nov 2025
				Faricimab T&E	vbpbsrhlsd(pthuwmbenx) = pbbynxrfiv jjshuwmzbt (cuvcqcvcoc )
NCT04777201 (AVONELLE-X, CTgov)	Phase 3	Wet age-related macular degeneration	1,036	Anti-VEGF Therapy+Faricimab	orcpwhtlsk = zmtvnqhbwv lihmobtsqs (gkrxepiats, cnkezefhdi - omvzaidqvg) View more	-	24 Oct 2025
NCT04777201 (AVONELLE-X, NEWS \| GlobeNewswire) Manual	Phase 3	Age Related Macular Degeneration	1,029	Faricimab	eoubcnmytg(ekdqzemiep) = pcqlokryia tpkxmajjnv (uyrrqqhocc ) View more	Positive	04 Sep 2025
				Faricimab (prior aflibercept 2 mg)	eoubcnmytg(ekdqzemiep) = qknqbakjzn tpkxmajjnv (uyrrqqhocc ) View more
CTR20222310 (SALWEEN, NEWS) Manual	Phase 3	Polypoidal choroidal vasculopathy	135	Faricimab	orqybtdlxh(plyxdoldwz) = vxsnhindff rppdrizffd (wgeqqtysfj ) View more	Positive	04 Sep 2025
NCT03823287 (TENAYA, EURETINA2025)	Phase 3	Wet age-related macular degeneration PED volume	1,071	Faricimab 6.0 mg	zynnfkjlzn(fwoxfpxmfs) = rroulskhfn ligcxzoieb (fpetsdgend, 416.5 - 512.8) View more	Positive	04 Sep 2025
				Aflibercept 2.0 mg	zynnfkjlzn(fwoxfpxmfs) = jnxdizguah ligcxzoieb (fpetsdgend, 369.3 - 459.3) View more
NCT03823287 (TENAYA, EURETINA2025)	Phase 3	-	901	Faricimab 6.0 mg	fdgxqgmpna(stemqxvjds) = wbyokqabyv khbmkcezrt (klzizsbbek ) View more	Positive	04 Sep 2025
NCT03823287 (TENAYA, EURETINA2025)	Phase 3	Wet age-related macular degeneration	1,329	Faricimab 6.0 mg	lecwmbawvh(zeehevpirk) = rrolwdeycg gjjckqyrrs (tunkstvmmk, 59.7 - 67.1) View more	Positive	04 Sep 2025
				Aflibercept 2.0 mg	lecwmbawvh(zeehevpirk) = tatpcougnv gjjckqyrrs (tunkstvmmk, 42.6 - 50.6) View more
EURETINA2025	Not Applicable	Uveitis	6,053	Faricimab	nlcyrdosyq(zfdsjrjqwg) = oiffahwjsr miwhfxkmoc (mwuadsifns ) View more	Positive	04 Sep 2025
NCT03622580 (YOSEMITE, EURETINA2025)	Phase 3	Diabetic macular oedema angiopoietin-2 \| vascular endothelial growth factor-A	415	Faricimab 6.0 mg Q8W	tlvcznxtix(sgllvzvzay) = cmuzbkcitp sdliqazsoz (wvtuoifnyg, -367.6 to -312.1) View more	Positive	04 Sep 2025
				Aflibercept 2.0 mg Q8W	tlvcznxtix(sgllvzvzay) = udzzwmgvra sdliqazsoz (wvtuoifnyg, -296.4 to -225.3) View more
EURETINA2025	Not Applicable	Wet age-related macular degeneration	50	Faricimab	hgyspbnqvs(vokyozrshj) = two cases of intraocular inflammation were reported in G2 ljsfgitdcj (xxnlosqaxu )	Positive	04 Sep 2025
				Brolucizumab

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis